Biological E. Limited

biologicale.com

Biological E. Limited (BE), the first private sector biological products company in India and the first pharmaceuticals company in South India was established in 1953. Originally incorporated as Biological Products Private Limited, and launched by Dr. Vijay Kumar Datla, today, BE is a globally recognised vaccine manufacturer and has supplied over 2 Billion Doses of Vaccines till date all over the world. BE supplies several essential and lifesaving Vaccines and Pharmaceuticals to UN Agencies viz. UNICEF, PAHO, many global markets, and in India to the National Immunization Program, various State Governments, PSUs, Indian Armed Forces and the domestic retail market.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Research

ADARE PHARMA SOLUTIONS ANNOUNCES DIVESTITURE OF POSTBIOTICS PIONEER ADARE BIOME TO DSM-FIRMENICH

prnewswire | July 04, 2023

news image

Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in nutrition, health, and beauty. The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x. Tom Sellig, CEO of Adare Pharma Solutions, commented: "dsm-firmenich...

Read More

Research

CIPHER PARTNER, MOBERG PHARMA ANNOUNCES APPROVAL FOR MOB-015 IN THE EUROPEAN UNION

Newswire | July 05, 2023

news image

Cipher Pharmaceuticals Inc. ("Cipher" or "the Company") today announced that the Company's partner, Moberg Pharma AB, ("Moberg Pharma") has obtained European Union approval for MOB-015 (nail fungus treatment) as a result of demonstrating superior levels of mycological cure (76% vs. 42% for comparators) and a significantly better complete cure rate. MOB-015 has been recommended for national approval in 13 European countries, which will be commerc...

Read More

Business Insights

AMYLYX PHARMACEUTICALS ANNOUNCES ALBRIOZA™ IS NOW AVAILABLE IN CANADA FOR THE TREATMENT OF ALS

Amylyx Pharmaceuticals, Inc | August 01, 2022

news image

Amylyx Pharmaceuticals, Inc. announced that ALBRIOZA™ is now commercially available in Canada for people living with amyotrophic lateral sclerosis. ALBRIOZA is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or when added to existing treatments. In a clinical trial, ALBRIOZA significantly slowed disease progression and loss of functional decline in people living with ALS. “We have remained steadfast in our commitment ...

Read More

CPD and Learning

POSTERA AND NEUROLUCENT PARTNERS ON IDENTIFYING SMALL-MOLECULE THERAPEUTICS FOR ALZHEIMER'S DISEASE

PostEra | November 27, 2020

news image

PostEra, a biotechnology organization offering restorative science fueled by AI, today reported a joint effort with NeuroLucent, a Chicago-put together organization centered with respect to creating novel medicines for Alzheimer's sickness and different dementias. The disappointment of late-stage clinical preliminaries to reveal viable treatments for Alzheimer's illness has underscored the need to investigate novel helpful methodologies. NeuroLucent is creating novel littl...

Read More
news image

Research

ADARE PHARMA SOLUTIONS ANNOUNCES DIVESTITURE OF POSTBIOTICS PIONEER ADARE BIOME TO DSM-FIRMENICH

prnewswire | July 04, 2023

Adare Pharma Solutions, a global technology-driven CDMO focused on oral dosage forms, today announced the completion of its divestiture of its Adare Biome business unit, a pioneer in the development and manufacturing of postbiotics, to dsm-firmenich, innovators in nutrition, health, and beauty. The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x. Tom Sellig, CEO of Adare Pharma Solutions, commented: "dsm-firmenich...

Read More
news image

Research

CIPHER PARTNER, MOBERG PHARMA ANNOUNCES APPROVAL FOR MOB-015 IN THE EUROPEAN UNION

Newswire | July 05, 2023

Cipher Pharmaceuticals Inc. ("Cipher" or "the Company") today announced that the Company's partner, Moberg Pharma AB, ("Moberg Pharma") has obtained European Union approval for MOB-015 (nail fungus treatment) as a result of demonstrating superior levels of mycological cure (76% vs. 42% for comparators) and a significantly better complete cure rate. MOB-015 has been recommended for national approval in 13 European countries, which will be commerc...

Read More
news image

Business Insights

AMYLYX PHARMACEUTICALS ANNOUNCES ALBRIOZA™ IS NOW AVAILABLE IN CANADA FOR THE TREATMENT OF ALS

Amylyx Pharmaceuticals, Inc | August 01, 2022

Amylyx Pharmaceuticals, Inc. announced that ALBRIOZA™ is now commercially available in Canada for people living with amyotrophic lateral sclerosis. ALBRIOZA is an oral fixed-dose combination therapy that may reduce neuronal cell death as a stand-alone therapy or when added to existing treatments. In a clinical trial, ALBRIOZA significantly slowed disease progression and loss of functional decline in people living with ALS. “We have remained steadfast in our commitment ...

Read More
news image

CPD and Learning

POSTERA AND NEUROLUCENT PARTNERS ON IDENTIFYING SMALL-MOLECULE THERAPEUTICS FOR ALZHEIMER'S DISEASE

PostEra | November 27, 2020

PostEra, a biotechnology organization offering restorative science fueled by AI, today reported a joint effort with NeuroLucent, a Chicago-put together organization centered with respect to creating novel medicines for Alzheimer's sickness and different dementias. The disappointment of late-stage clinical preliminaries to reveal viable treatments for Alzheimer's illness has underscored the need to investigate novel helpful methodologies. NeuroLucent is creating novel littl...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us